Login

Akili, Inc. 8-K SEC Filings

Filed On Filing
02 Jul 2024 8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +5 more

Registered Office. The corporation shall maintain a registered office and registered agent in the State of Delaware. The registered office and/or registered agent of the corporation may be changed from time to time by action of the board...

18 Jun 2024 8-K: Other Events

Clinically proven to improve attention function, EndeavorOTC® is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD

29 May 2024 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This AGREEMENT AND PLAN OF MERGER, dated as of May 29, 2024 (this “Agreement” and, such date, the “Agreement Date”), by and among Virtual Therapeutics Corporation, a Delaware corporation (“Parent”), Alpha Merger Sub, Inc., a Delaware cor...

14 May 2024 8-K: Results of Operations and Financial Condition

Company announces full voluntary prepayment of debt and termination of Amended & Restated

30 Apr 2024 8-K: Entry into a Material Definitive Agreement; Costs Associated with Exit or Disposal Activities +1 more

Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results

23 Apr 2024 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Submission of Matters to a Vote of Security Holders

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

29 Feb 2024 8-K: Results of Operations and Financial Condition

FY 2023 total revenues of $1.7M, a 420% increase over FY 2022 as EndeavorOTC® gained traction in the market following June 2023 product release

26 Feb 2024 8-K: Other Events

Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan

21 Feb 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Plans to disclose Q4/FY 2023 financial results on February 29, 2024; CEO Matthew Franklin to participate in fireside chat at TD Cowen’s 44th Annual Healthcare Conference on March 4, 2024

05 Jan 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

20 Dec 2023 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Departure/Election of Directors or Officers; Compensation

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

18 Dec 2023 8-K: Other Events

EndeavorRx®, World’s First and Only Prescription Video Game Treatment, Secures FDA Label Expansion for Pediatric ADHD Patients Aged 13-17

09 Nov 2023 8-K: Results of Operations and Financial Condition

Reports third quarter total revenues of $702 thousand, representing more than 5x growth over

27 Oct 2023 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On October 24, 2023, Akili, Inc. (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the 30 consecutive business days from...

06 Oct 2023 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Co-founder and CEO Eddie Martucci, Ph.D. transitions to role of Board chair; Matt Franklin, president and chief operating officer of Akili, appointed president and chief executive officer

13 Sep 2023 8-K: Costs Associated with Exit or Disposal Activities; Other Events

Non-prescription model will increase patient access to clinically-validated non-drug treatments and reduce Akili’s reliance on intermediaries

10 Aug 2023 8-K: Results of Operations and Financial Condition

EndeavorRx® prescriptions in pediatric ADHD market grew 27% in Q2 2023 over Q1 2023

07 Jun 2023 8-K: Regulation FD Disclosure; Other Events

Amid growing mental health crisis, the product release enables immediate access to non-drug treatment option as Akili prepares FDA submission

11 May 2023 8-K: Results of Operations and Financial Condition

EndeavorRx® prescriptions for children with ADHD increased 32% in Q1 2023 over Q4 2022

04 May 2023 8-K: Submission of Matters to a Vote of Security Holders

On May 2, 2023, Akili, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders voted on the following two proposals: (1) to elect tw...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support